Education
About Us
Working with TipRanks
Follow Us
ImmuPharma PLC (GB:IMM)
LSE:IMM
IMM Stock Chart & Stats
6.20p
0.95p(79.03%)
At close: 4:00 PM EST
6.20p
0.95p(79.03%)
Day’s Range― - ―
52-Week Range1.39p - 19.40p
Previous CloseN/A
Volume11.77M
Average Volume (3M)15.00M
Market Cap
£35.14M
Enterprise Value34.74M
Total Cash (Recent Filing)£396.65K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.50
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding502,723,940
10 Day Avg. Volume4,827,745
30 Day Avg. Volume14,996,625
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-9.23
Price to Sales (P/S)0.00
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Minimal DebtNear-zero reported debt reduces fixed interest costs and financial distress risk, preserving flexibility. For a clinical-stage biotech this allows management to prioritize R&D and partner negotiations without immediate debt servicing constraints, supporting longer-term program funding options.
Improving Operating LossesNarrowing losses vs prior years indicates disciplined cost control and more efficient program spending. This trend lengthens runway per unit of funding, increases the chance of reaching clinical or partnering milestones before additional dilutive financings are required, a durable operational improvement.
Partnership/licensing Business ModelA partnering-centric model lets the company de‑risk late-stage development and commercialization by leveraging partner scale and capital. Structurally, this enables capital-efficient progress of candidates and potential milestone/royalty upside without building large commercial infrastructure.
Bears Say
Absent Recurring RevenueA near-zero revenue base removes any recurring cash cushion and makes the company wholly dependent on milestone, partner payments or financings. This structurally limits self‑funding capacity and increases execution risk if anticipated transactions or partnerships do not materialize.
Negative Shareholders' EquityNegative equity signals accumulated losses and a weakened balance sheet, reducing borrowing capacity and counterparties' confidence. Over months this can constrain strategic options, increase cost of capital, and force more dilutive financings to sustain R&D and operations.
Persistent Cash BurnConsistent negative operating and free cash flow requires external funding to continue development programs. Structurally, ongoing burn increases dilution risk, can delay or curtail trials if funding gaps occur, and places pressure on management to secure partnerships or financing on favorable terms.
ImmuPharma News
IMM FAQ
What was ImmuPharma PLC’s price range in the past 12 months?
ImmuPharma PLC lowest share price was 1.39p and its highest was 19.40p in the past 12 months.
What is ImmuPharma PLC’s market cap?
ImmuPharma PLC’s market cap is £35.14M.
When is ImmuPharma PLC’s upcoming earnings report date?
ImmuPharma PLC’s upcoming earnings report date is May 26, 2026 which is in 98 days.
How were ImmuPharma PLC’s earnings last quarter?
ImmuPharma PLC released its earnings results on Aug 06, 2025. The company reported -0.004p earnings per share for the quarter, missing the consensus estimate of N/A by -0.004p.
Is ImmuPharma PLC overvalued?
According to Wall Street analysts ImmuPharma PLC’s price is currently Overvalued.
Does ImmuPharma PLC pay dividends?
ImmuPharma PLC pays a Notavailable dividend of 1p which represents an annual dividend yield of N/A. See more information on ImmuPharma PLC dividends here
What is ImmuPharma PLC’s EPS estimate?
ImmuPharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma PLC have?
ImmuPharma PLC has 502,723,940 shares outstanding.
What happened to ImmuPharma PLC’s price movement after its last earnings report?
ImmuPharma PLC reported an EPS of -0.004p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -18.894%.
Which hedge fund is a major shareholder of ImmuPharma PLC?
Currently, no hedge funds are holding shares in GB:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmuPharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
507.23%
12-Months-Change
Fundamentals
Return on Equity
-259.88%
Trailing 12-Months
Asset Growth
-61.09%
Trailing 12-Months
Company Description
ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Technical Analysis
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
SkinBioTherapeutics
―
Poolbeg Pharma Ltd.
―